Get the Stockscreener App
0.238
4.29%
0.0098
After Hours:
.23
-0.008
-3.36%
Tscan Therapeutics Inc stock is traded at $0.238, with a volume of 869.28K.
It is up +4.29% in the last 24 hours and down -27.90% over the past month.
TScan Therapeutics Inc is a fully integrated clinical-stage biotechnology company focused on developing a robust pipeline of T cell receptor (TCR)-engineered T cell, or TCR-T, therapies for the treatment of patients with cancer. The company's liquid tumor TCR-T therapy candidates, TSC-100 and TSC-101, are in development for the treatment of patients with hematologic malignancies to eliminate residual leukemia and prevent relapse after hematopoietic stem cell transplantation. It is also developing multiplexed TCR-T therapy candidates for the treatment of various solid tumors.
See More
Previous Close:
$0.2282
Open:
$0.2282
24h Volume:
869.28K
Relative Volume:
1.29
Market Cap:
$16.13M
Revenue:
$9.14M
Net Income/Loss:
$-124.31M
P/E Ratio:
-0.2486
EPS:
-0.9573
Net Cash Flow:
$-125.43M
1W Performance:
-25.74%
1M Performance:
-27.90%
6M Performance:
-77.55%
1Y Performance:
-89.03%
1-Day Range:
$0.2279
$0.2474
1-Week Range:
$0.2243
$0.33
52-Week Range:
$0.2243
$2.57
Tscan Therapeutics Inc Stock (TCRX) Company Profile
Name
Tscan Therapeutics Inc
Sector
Industry
Phone
857-399-9500
Address
830 WINTER STREET, WALTHAM
Compare TCRX vs VRTX, MRNA, REGN, ARGX, RVMD
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
TCRX
Tscan Therapeutics Inc
|
0.238 | 16.13M | 9.14M | -124.31M | -125.43M | -0.9573 |
VRTX
Vertex Pharmaceuticals Inc
|
510.08 | 129.29B | 12.34B | 4.34B | 3.71B | 16.87 |
MRNA
Moderna Inc
|
225.00 | 89.83B | 2.23B | -3.19B | -1.60B | -8.1462 |
REGN
Regeneron Pharmaceuticals Inc
|
746.54 | 76.86B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
825.03 | 51.88B | 4.16B | 1.29B | 734.26M | 19.58 |
RVMD
Revolution Medicines Inc
|
189.76 | 40.67B | 742.00K | -1.37B | -1.07B | -7.0731 |
Tscan Therapeutics Inc Stock (TCRX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Sep-08-26 | Downgrade | H.C. Wainwright | Buy → Neutral |
| Nov-14-25 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| May-16-24 | Initiated | BTIG Research | Buy |
| May-13-24 | Initiated | Needham | Buy |
| Jun-22-23 | Initiated | Wedbush | Outperform |
Tscan Therapeutics Inc Stock (TCRX) Latest News
Tscan Therapeutics Inc (NASDAQ: TCRX) Stock Price, News & Analysis - Kalkine
TScan Therapeutics announces retention program for key executives - Investing.com
Form 8K Tscan Therapeutics Inc For: 11 September By Investing.com - Investing.com Australia
TScan Therapeutics Launches Executive Retention Incentive Program - TipRanks
TScan Therapeutics announces retention program for key executives By Investing.com - Investing.com India
Form 8K Tscan Therapeutics Inc For: 11 September By Investing.com - Investing.com India
TScan Therapeutics announces retention program for key executives By Investing.com - Investing.com UK
TScan Therapeutics announces retention program for key executives - Investing.com
TScan Therapeutics grants retention awards to CEO Gavin MacBeath and CLO Zoran Zdraveski - TradingView
New milestone-tied pay plan for TScan Therapeutics (TCRX) leaders - Stock Titan
Form 8K Tscan Therapeutics Inc For: 11 September By Investing.com - Investing.com South Africa
TSCAN THERAPEUTICS INC : H.C. WAINWRIGHT CUTS TARGET PRICE TO $1 FROM $7 - webull.com
H.C. Wainwright Downgrades TScan Therapeutics(TCRX.US) to Hold Rating, Cuts Target Price to $1 - Moomoo
H.C. Wainwright downgrades Tscan stock rating on restructuring - Investing.com
H.C. Wainwright downgrades Tscan stock rating on restructuring By Investing.com - Investing.com Canada
H.C. Wainwright downgrades Tscan stock rating on restructuring - Investing.com India
H.C. Wainwright downgrades Tscan stock rating on restructuring By Investing.com - Investing.com UK
H.C. Wainwright downgrades Tscan stock rating on restructuring By Investing.com - Investing.com South Africa
TScan Therapeutics, Inc. (TCRX) Discusses Strategic Refocus on In Vivo Cell Therapy for Solid Tumors and Pausing of Phase III Heme StudySlideshow (NASDAQ:TCRX) 2026-09-04 - Seeking Alpha
TScan Therapeutics Cuts 75% of Staff, Pivots to In Vivo TCR-T for Solid Tumors - BioPharm International
TCRX Downgraded by Wedbush -- Price Target Lowered to $1.00 - GuruFocus
Tscan prioritizes in vivo solid tumor program - BioWorld News
TScan Therapeutics IncExpects to Incur Abo - Moomoo
TScan Therapeutics sheds majority of staff, pauses Phase 3 trial amid funding shortfall - The Business Journals
Tscan Therapeutics stock rating cut to neutral by Wedbush on strategy shift - Investing.com Nigeria
Crude Oil Moves Higher; US Factory Orders Rise In July - Benzinga
TScan Reorganizes Pipeline Priorities, Implements Workforce Reduction - Benzinga
Tscan Therapeutics stock rating cut to neutral by Wedbush on strategy shift - Investing.com South Africa
Tscan Therapeutics stock rating cut to neutral by Wedbush on strategy shift - Investing.com
Tscan Therapeutics stock rating cut to neutral by Wedbush on strategy shift - Investing.com Canada
Tscan Therapeutics stock rating cut to neutral by Wedbush on strategy shift - Investing.com UK
Why is TScan Therapeutics stock collapsing today? By Investing.com - Investing.com Canada
Why is TScan Therapeutics stock collapsing today? By Investing.com - Investing.com UK
TScan Therapeutics Cuts Workforce by 75% and Shifts Focus to Solid Tumor Program - Yahoo Finance
TScan Therapeutics Restructures to Focus on Solid Tumors - TipRanks
TScan Therapeutics Disclosed Failure to Satisfy a Continued Listing Rule or Standard - TradingView
TScan Therapeutics Announces Strategic Reorganization to Focus on in vivo Cell Therapy for Solid Tumors - GlobeNewswire
TScan Therapeutics highlights push into in vivo-engineered TCR-T cell therapy for solid tumors in corporate presentation - Bitget
TScan Therapeutics Announces Positive Initial Data from Cohort C of Ongoing ALLOHA™ Phase 1 Study Evaluating TSC-101 in Patients with Heme Malignancies Undergoing Allogeneic Hematopoietic Cell Transplantation - Barchart.com
TScan Therapeutics (TCRX) Holds at $0.75 as Biotech Stock Defends Key SupportSell Signal Alerts - dars.gov.et
TScan Therapeutics (TCRX) Holds at $0.75 as Biotech Stock Defends Key SupportWave Extension - vinanet.vn
Why Is Amgen (AMGN) Ending Its Crohn's Disease Research Partnership? - Yahoo Finance
Is Amgen (AMGN) Refocusing Its R&D Portfolio With The Exit From TScan’s Crohn’s Deal? - simplywall.st
Amgen abandoning $500M+ Crohn’s collab won’t derail TScan’s pipeline strategy - Fierce Biotech
Amgen cans its TScan partnership; Amylyx reveals $350M offering - Endpoints News
TScan Therapeutics Faces Loss of Key Amgen Partnership - TipRanks
TScan TherapeuticsAmgen To Terminate Research Collaboration And License Agreement With TScan TherapeuticsSEC Filing - TradingView
TScan (NASDAQ: TCRX) loses Amgen Crohn’s collaboration - Stock Titan
TScan Therapeutics (TCRX) Edges Higher, Holding Support at $0.74Up Down Volume - vinanet.vn
TScan Therapeutics (TCRX) Edges Higher, Holding Support at $0.74Volume Weighted Price - dars.gov.et
Tscan Therapeutics Inc Stock (TCRX) Financials Data
Revenue
Net Income
Cash Flow
EPS
Tscan Therapeutics Inc Stock (TCRX) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Lynx1 Capital Management LP | 10% Owner |
Dec 23 '25 |
Buy |
0.90 |
6,232 |
5,602 |
8,019,148 |
| Lynx1 Capital Management LP | 10% Owner |
Dec 22 '25 |
Buy |
0.90 |
75,500 |
67,950 |
8,012,916 |
1.64%
0.29%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):